Anshul Bhardwaj
Overview
Explore the profile of Anshul Bhardwaj including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
576
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Davern M, O Donovan C, Donlon N, Mylod E, Gaughan C, Bhardwaj A, et al.
Biomedicines
. 2024 Apr;
12(4).
PMID: 38672174
The presence of an immunosuppressive tumour microenvironment in oesophageal adenocarcinoma (OAC) is a major contributor to poor responses. Novel treatment strategies are required to supplement current regimens and improve patient...
2.
Donlon N, Davern M, Sheppard A, OConnell F, Moran B, Nugent T, et al.
World J Gastrointest Oncol
. 2023 Sep;
15(8):1349-1365.
PMID: 37663943
Background: There is an intimate crosstalk between cancer formation, dissemination, treatment response and the host immune system, with inducing tumour cell death the ultimate therapeutic goal for most anti-cancer treatments....
3.
OConnell F, Mylod E, Donlon N, Heeran A, Butler C, Bhardwaj A, et al.
Cancers (Basel)
. 2023 Mar;
15(6).
PMID: 36980567
Oesophageal adenocarcinoma (OAC) is a poor prognosis cancer with limited response rates to current treatment modalities and has a strong link to obesity. To better elucidate the role of visceral...
4.
Davern M, Bracken-Clarke D, Donlon N, Sheppard A, O Connell F, Heeran A, et al.
J Cancer Res Clin Oncol
. 2023 Feb;
149(9):6583-6599.
PMID: 36790524
Aim: Visceral obesity is a key risk factor in the development of oesophagogastric junctional adenocarcinoma (OGJ), predominantly via generation of systemic low grade inflammation. Obesity-induced inflammation promotes resistance to current...
5.
Davern M, Donlon N, OConnell F, Gaughan C, ODonovan C, McGrath J, et al.
J Cancer Res Clin Oncol
. 2022 Nov;
149(8):5377-5395.
PMID: 36445478
Aim: Use of immune checkpoint blockade to enhance T cell-mediated immunity within the hostile tumour microenvironment (TME) is an attractive approach in oesophageal adenocarcinoma (OAC). This study explored the effects...
6.
Davern M, Donlon N, Sheppard A, Majcher K, O Connell F, Heeran A, et al.
J Cancer Res Clin Oncol
. 2022 Aug;
149(7):3753-3774.
PMID: 35986757
Combining immunostimulatory chemotherapies with immunotherapy is an attractive strategy to enhance treatment responses in oesophagogastric junctional adenocarcinoma (OGJ). This study investigates the immunostimulatory properties of FLOT, CROSS and MAGIC chemotherapy...
7.
Guo N, Minas G, Synowsky S, Dunne M, Ahmed H, McShane R, et al.
J Proteomics
. 2022 Jul;
266:104684.
PMID: 35842220
Oesophageal adenocarcinoma (OAC) is an aggressive cancer with a five-year survival of <15%. Current chemotherapeutic strategies only benefit a minority (20-30%) of patients and there are no methods available to...
8.
Donlon N, Davern M, OConnell F, Sheppard A, Heeran A, Bhardwaj A, et al.
World J Gastroenterol
. 2022 Jul;
28(21):2302-2319.
PMID: 35800186
Background: In the contemporary era of cancer immunotherapy, an abundance of clinical and translational studies have reported radiotherapy (RT) and immunotherapies as a viable option for immunomodulation of many cancer...
9.
Davern M, Donlon N, OConnell F, Gaughan C, ODonovan C, Habash M, et al.
Cancer Immunol Immunother
. 2022 Jun;
72(1):55-71.
PMID: 35708739
Tumour acidosis contributes to cancer progression by inhibiting anti-tumour immunity. However, the effect of acidosis on anti-tumour T cell phenotypes in oesophageal adenocarcinoma (OAC) is unknown. Therefore, this study investigated...
10.
Davern M, Donlon N, O Connell F, Sheppard A, Hayes C, King R, et al.
Transl Oncol
. 2022 Apr;
20:101406.
PMID: 35366537
Response rates to immune checkpoint blockade (ICB) remain low in oesophageal adenocarcinoma (OAC). Combining ICB with immunostimulatory chemotherapies to boost response rates is an attractive approach for converting 'cold' tumours...